Page 268 - Drug Class Review
P. 268
Page 164 of 205
Drug Effectiveness Review Project
donepezil 16.1 15.5 7.4 5.6 5.0 5.0 5.0 5.0 Post randomization exclusions: N/A Overall loss to follow-up: N/A Loss to follow-up differential high: N/A donepezil N/A N/A
ITT: N/A
N/A N/A N/A N/A N/A
Final Report Update 1 Authors: Dunn et al. Year:2000 ADVERSE EVENTS: Overall adverse effects reported: Nausea/Vomiting • Diarrhea • Malaise/lassitude • Respiratory tract infection • Dizziness • Insomnia • Micturition disorder • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drug
